Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Deborah F. Chapman"'
Autor:
Mark A. Varney, Nicholas D. P. Cosford, Jeffery J. Anderson, Una Campbell, Margaret J. Bradbury, Deborah F. Chapman, Lida R. Tehrani, Darlene R. Giracello, Christopher D. King, A. M. Strack
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 313:395-402
The metabotropic glutamate receptor subtype mGlu5 modulates central reward pathways. Many transmitter systems within reward pathways affect feeding. We examined the potential role of mGlu5 in body weight regulation using genetic and pharmacological a
Autor:
Jeffrey Roger Roppe, Nicholas D. P. Cosford, Lida R. Tehrani, Deborah F. Chapman, Merryl Cramer, Nicholas D. Smith, Steve F. Poon, Thomas S. Reger, Dehua Huang, Janice Chung
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 14:5473-5476
Structure–activity relationship studies on 3-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 2 led to the discovery of 2-{2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl}pyridine (10)—a highly potent and selective mGlu5 receptor antagonist with good
Autor:
Jeffery J. Anderson, Mark A. Varney, Christopher D. King, Margaret J. Bradbury, Deborah F. Chapman, Greg Holtz, Nicholas D. P. Cosford, Jeffrey R. Roppe, Darlene R. Giracello
Publikováno v:
European Journal of Pharmacology. 473:35-40
In vivo receptor occupancy of mGlu5 receptor antagonists was quantified in rat and mouse brain using the mGlu5 receptor selective antagonist [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine) ([3H]methoxy-PEPy). Administration of [3H]methoxy-PEPy (50 mic
Autor:
Darlene R. Giracello, Blake A. Rowe, Nicholas D. P. Cosford, Mark A. Varney, Deborah F. Chapman, Margaret J. Bradbury, Jeffery J. Anderson, Lida R. Tehrani, Greg Holtz, Sara P. Rao
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 303:1044-1051
The binding of [3H]methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (methoxymethyl-MTEP), a potent and selective antagonist for metabotropic glutamate (mGlu)5 receptors, was characterized in rat brain both in vitro and in vivo. Nonspecifi
Autor:
Harold Thibodeaux, Patrick D. Lyden, Deborah F. Chapman, Paul A. Lapchak, Sonia Nunez, Justin A. Zivin
Publikováno v:
Scopus-Elsevier
Background and Purpose —Tissue plasminogen activator (tPA) is an effective treatment for stroke, but its utility is limited by fear of cerebral hemorrhage. Tenecteplase (TNK), a genetically modified form of wild-type tPA, exhibits a longer biologic
Publikováno v:
Stroke. 32:147-153
Background and Purpose —It has been proposed that spin trap agents such as N -t-butyl-phenylnitrone (PBN) may be useful as neuroprotective agents in the treatment of ischemia and stroke. However, to date, there is little information concerning the
Publikováno v:
Stroke. 31:1953-1957
Background and Purpose —Dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS) may function as neurotrophic or neuroprotective factors to protect central nervous system (CNS) neurons against a variety of insults, including excitotoxicity. The prese
Publikováno v:
Psychological Reports. 76:483-492
Data on measures of organizational culture and organizational performance were collected at two different points in time from a sample of 12 organizations of a firm in the electric utility industry. Pearson correlations indicated measures of organiza
Autor:
Merryl Cramer, Jeffrey Roger Roppe, Lida R. Tehrani, Nicholas D. Smith, Dehua Huang, Thomas Jon Seiders, Steve F. Poon, Deborah F. Chapman, Janice Chung, Nicholas D. P. Cosford
Publikováno v:
Bioorganicmedicinal chemistry letters. 15(22)
Structure-activity relationship studies on the phenyl ring of 3-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 2 led to the discovery that small, non-hydrogen bond donor substituents at the 3-position led to a substantial increase in in vitro potency.
Autor:
Brian W. Eastman, Nicholas D. Smith, Steve F. Poon, Janice Chung, Nicholas D. P. Cosford, Gregory Holtz, Deborah F. Chapman, Merryl Cramer
Publikováno v:
Bioorganicmedicinal chemistry letters. 14(22)
Structure-activity relationship studies performed around 3-fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile for the purpose of developing novel mGlu5 receptor antagonists are described. Synthesis of a series of four-ring tetrazoles led to the d